Holen Sie sich die Stockscreener-App
13.38
7.28%
-1.05
Vorhandelsmarkt:
13.08
-0.30
-2.24%
Schlusskurs vom Vortag:
$14.43
Offen:
$14.43
24-Stunden-Volumen:
3.92M
Relative Volume:
0.58
Marktkapitalisierung:
$4.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-277.02M
KGV:
-14.34
EPS:
-0.9328
Netto-Cashflow:
$-91.36M
1W Leistung:
-0.22%
1M Leistung:
+30.79%
6M Leistung:
+280.11%
1J Leistung:
+852.31%
1-Tages-Spanne:
$13.32
$14.52
1-Wochen-Bereich:
$13.00
$14.60
52-Wochen-Spanne:
$1.21
$24.28
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
13.38 | 4.49B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
ERAS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Erasca, Inc. - Morningstar
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. - GlobeNewswire
Erasca, Inc. (ERAS) Faces Securities Class Action Amid - GlobeNewswire
ERAS Shareholder Alert: Erasca, Inc. Securities Class - GlobeNewswire
Erasca, Inc. (ERAS) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 10, 2026 Deadline - ACCESS Newswire
INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitRGRD Law - marketscreener.com
INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with - GlobeNewswire
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
Frazier Life Sciences Management, L.P.'s Erasca Inc(ERAS) Holding History - GuruFocus
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - The Malaysian Reserve
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
FinancialContentErasca, Inc. (ERAS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Erasca, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Berger Montague PC Investigating Claims on Behalf of Erasca, Inc. (ERAS) Investors After Class Action Filing - marketscreener.com
Class action lawsuit filed against Erasca over misleading drug claims affecting investors. - Pluang
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Killeen Daily Herald
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit - Morningstar
INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - The Norfolk Daily News
Rosen Law Firm Urges Erasca, Inc. (NASDAQ: ERAS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Joplin Globe
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Los - GuruFocus
ERAS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Erasca (ERA) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - 巴士的報
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
ERAS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Class action lawsuit filed against Erasca over alleged false statements and patent issues. - Pluang
Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit - The Joplin Globe
Erasca sued for securities fraud over misleading drug claims, stock drops 45%. - Pluang
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 10 ... - Caledonian Record
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud - GlobeNewswire
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
Erasca Inc. (ERAS) Faces Selling Pressure as Shares Decline 3%KAMA Signal - newsline.com
BofA Securities Maintains Erasca(ERAS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents - Yahoo Finance
Venrock Adviser, LLC's Erasca Inc(ERAS) Holding History - GuruFocus
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations - Insider Monkey
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Erasca earnings on deck after ERAS-0015 data sparks debate - Investing.com
Erasca earnings on deck after ERAS-0015 data sparks debate By Investing.com - Investing.com Nigeria
Erasca Shares Rise After BofA Upgrade - Moomoo
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset - Barchart.com
Erasca, Inc. Stock 12‑Month Price Target Raised to $20.91, Implies 59% Upside - TradingView
BofA Securities Upgrades Erasca(ERAS.US) to Hold Rating, Raises Target Price to $16 - Moomoo
BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9 - marketscreener.com
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):